In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates.

Quinupristin/dalfopristin (RP59500) is a novel streptogramin and a semisynthetic derivative of pristinamycins IA and IIB. The following properties of RP59500 were investigated: (i) its in-vitro activity against 164 hospital isolates of Staphylococcus aureus, 101 of which were methicillin-resistant (MRSA); (ii) its killing effect against 24 MRSA and seven methicillin-susceptible (MSSA) isolates; (iii) its interactions with rifampicin and ciprofloxacin against 18 MRSA isolates, six susceptible to both rifampicin and ciprofloxacin and 12 resistant to both, at 1 x MIC, 2 x MIC and 4 x MIC. Rifampicin and ciprofloxacin were applied at a concentration equal to their mean serum levels in order to establish the clinical relevance of the results. The MIC50, MIC90, MBC50 and MBC90 of quinupristin/dalfopristin were, respectively, < or = 0.015, 2, 0.12 and 2 mg/L for MRSA isolates and < or = 0.015, 0.06, < or = 0.015 and 0.25 mg/L for MSSA isolates. All isolates were inhibited by quinupristin/dalfopristin. Its killing effect varied with concentration and time, being optimal at 4 x MIC and after 24 h growth. Strains surviving 24 h exposure to this agent had much higher MICs than the parent strain, but only a limited number of them became resistant. Quinupristin/dalfopristin at 2 x MIC and 4 x MIC showed in-vitro synergy with rifampicin against highly resistant isolates mainly at 6 h and 24 h of growth involving 50-83% of MRSA isolates, and showed synergy with ciprofloxacin at 24 h involving 42-75% of isolates. The MIC increase in colonies surviving at 24 h was restricted by the presence of rifampicin or ciprofloxacin. In contrast, the above combinations acted synergically over the total number of MRSA strains susceptible to both rifampicin and ciprofloxacin. The above findings show that quinupristin/dalfopristin is a very potent antistaphylococcal agent, and that its activity against MRSA isolates is enhanced when it is combined with rifampicin or ciprofloxacin.

[1]  P. Appelbaum.  Emerging Resistance to Antimicrobial Agents in Gram-Positive Bacteria , 2012, Drugs.

[2]  R. Finch.  Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use. , 1996, Drugs.

[3]  J. Pechère.  Streptogramins. A unique class of antibiotics. , 1996, Drugs.

[4]  J. Desnottes,et al.  Bactericidal activity and kinetics of RP 59500 in a mouse model of Staphylococcus aureus septicaemia. , 1995, The Journal of antimicrobial chemotherapy.

[5]  G. Woods.  Antibacterial susceptibility tests : Dilution and disk diffusion methods. , 1995 .

[6]  K. Aldridge,et al.  In vitro antistaphylococcal activity and testing of RP 59500, a new streptogramin, by two methods , 1992, Antimicrobial Agents and Chemotherapy.

[7]  S. Mitsuhashi,et al.  Comparative in-vitro activity of RP 59500 against clinical bacterial isolates. , 1992, The Journal of antimicrobial chemotherapy.

[8]  J. Hamilton-miller,et al.  In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria. , 1992, The Journal of antimicrobial chemotherapy.

[9]  H. Neu,et al.  The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination. , 1992, Journal of Antimicrobial Chemotherapy.

[10]  S. Miyazaki,et al.  The in-vitro activity of RP 59500 against gram-positive cocci. , 1992, The Journal of antimicrobial chemotherapy.

[11]  J. Duval,et al.  Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics. , 1992, The Journal of antimicrobial chemotherapy.

[12]  J. Verhaegen,et al.  Comparative in-vitro activity of RP 59500. , 1992, The Journal of antimicrobial chemotherapy.

[13]  H. Larson,et al.  Pathology of the Liver , 1980 .